Actavis wants out of China

Share this article:

Actavis wants out of China. Bloomberg reports that the generics drugmaker said the country's business climate is too difficult to continue to operate in. “It wasn't worth the aggravation, the frustration or the concern,” CEO Paul Bisaro told Bloomberg at the JP Morgan Healthcare conference.

Bisaro added: “If we are going to allocate capital, we're going to do so where we can get the most amount of return for the least amount of risk. And China is just too risky.”

Bloomberg notes that Actavis has not been among the companies slammed with accusations of corruption and that the country makes up a small portion of the firm's business.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.